



## **Probiotics in late infancy reduce the incidence of eczema**

### **A randomized controlled trial**

Schmidt, Rikke Meineche; Laursen, Rikke Pilmann; Bruun, Signe; Larnkjær, Anni; Mølgaard, Christian; Michaelsen, Kim F.; Høst, Arne

*Published in:*  
Pediatric Allergy and Immunology

*DOI:*  
[10.1111/pai.13018](https://doi.org/10.1111/pai.13018)

*Publication date:*  
2019

*Document version*  
Peer reviewed version

*Citation for published version (APA):*  
Schmidt, R. M., Laursen, R. P., Bruun, S., Larnkjær, A., Mølgaard, C., Michaelsen, K. F., & Høst, A. (2019). Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. *Pediatric Allergy and Immunology*, 30(3), 335-340. <https://doi.org/10.1111/pai.13018>



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

DR RIKKE MEINECHE SCHMIDT (Orcid ID : 0000-0003-4372-2356)

Article type : Original

### Title page

Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial

Rikke Meineche Schmidt<sup>1</sup>, Rikke Pilmann Laursen<sup>2</sup>, Signe Bruun<sup>1,3</sup>, Anni Larnkjær<sup>2</sup>, Christian Mølgaard<sup>2</sup>, Kim F. Michaelsen<sup>2</sup>, Arne Høst<sup>1,3</sup>

1) Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark

2) Department of Nutrition, Exercise and Sports, Faculty of Science,  
University of Copenhagen, Denmark

3) Department of Clinical Research, Faculty of Health Sciences,  
University of Southern Denmark, Odense, Denmark

Running title: Probiotic prevention of allergic disease

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/PAI.13018](https://doi.org/10.1111/PAI.13018)

This article is protected by copyright. All rights reserved

23 Correspondence to: Rikke Meineche Schmidt, Hans Christian Andersen Children's Hospital,  
24 Odense University Hospital, Kløvervænget 23C, entrance 60, DK-5000 Odense C, Denmark, e-mail  
25 [rikke.m.schmidt@rsyd.dk](mailto:rikke.m.schmidt@rsyd.dk)

26

27

Count: 2,433 words and 2 tables

28

## Abstract page

29

30 Schmidt RM, Laursen RP, Bruun S, Larnkjær A, Mølgaard C, Michaelsen KF, Høst A.

31 Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial

32

Pediatr Allergy Immunol

33

## 34 ABSTRACT

### 35 *Background*

36 Allergic diseases are common and represent a considerable health and economic burden worldwide.  
37 We aimed to examine the effect of a combination of two probiotic strains administered in late  
38 infancy and early childhood on the development of allergic diseases and sensitization.

### 39 *Methods*

40 In this double-blind, placebo-controlled intervention trial, participants were randomized to receive a  
41 daily mixture of *Lactobacillus rhamnosus* and *Bifidobacterium animalis* subsp. *lactis* or placebo –  
42 starting prior to attending daycare. The intervention period was 6 months, and the parents answered  
43 web-based questionnaires on allergic symptoms and doctor's diagnosed allergic disease monthly.  
44 IgE was measured at baseline and follow-up.

### 45 *Results*

46 A total of 290 participants were randomized; 144 in the probiotic group and 146 in the placebo  
47 group. Mean age at intervention start was 10.1 months. At follow-up (mean age 16.1 months), the  
48 incidence of eczema was 4.2% in the probiotic group and 11.5% in the placebo group ( $p = 0.036$ ).  
49 The incidence of asthma and conjunctivitis did not differ between groups, and no children presented  
50 with rhinitis. Sensitization was equal in the two groups at intervention start (7.5% and 9.5%  
51 respectively), and two children in each group were sensitized during the intervention.

## 52 *Conclusions*

53 We observed a significantly lower incidence of eczema in the probiotic group compared to the  
54 placebo group. The probiotics were administered in late infancy – prior to attending day care –  
55 suggesting a broader window of opportunity using probiotics in the prevention of eczema. The  
56 incidence of asthma, rhinitis, conjunctivitis and sensitization did not differ.

57

## 58 *Clinical Trial Registration*

59 Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare  
60 (ProbiComp), NCT02180581. <https://clinicaltrials.gov/ct2/show/NCT02180581>

61

62

## **Keywords**

63 Allergy, allergic diseases, atopy, *Bifidobacterium animalis* subsp. *lactis*, *Lactobacillus rhamnosus*,  
64 RCT, sensitization

## 65 **INTRODUCTION**

66 Allergic diseases in childhood consist of eczema, asthma, rhino-conjunctivitis and food allergies. In  
67 2014 it was estimated, that 11.6% of children under the age of 18 years suffer from eczema, 8.4%  
68 from rhinitis, 10% from respiratory allergies, and 5.4% from food allergies in the United States (1).  
69 In a 2015 estimate, one third of children in Denmark and Sweden was affected by at least one  
70 allergic disease at 5 years of age (2). Allergic diseases present a considerable health and economic  
71 burden; and might diminish the quality of life (3, 4), making the prevention of the development of  
72 these diseases an important task.

73 In the last decades, the interest in the preventive effects of probiotics (defined by the World Health  
74 Organization (WHO) as “live microorganisms which when administered in adequate amounts  
75 confer a health benefit on the host” (5)) has increased.

76 In 2012, Pelucchi *et al.* published a meta-analysis on the use of probiotics in prevention of atopic  
77 dermatitis (6). They concluded that probiotics play a moderate role in preventing atopic dermatitis if  
78 administered in pregnancy/early life to mother, child or both. A similar conclusion was drawn by  
79 Cuallo-Garcia *et al.* in a systematic review and meta-analysis from 2015, whereas no preventive  
80 effect on other allergic diseases was observed (7).

81 Due to the beneficial effects on the development of eczema, The World Allergy Organization  
82 guideline panel suggested in 2015 to use probiotics in pregnant women at high risk of having an  
83 allergic child; women, who breastfeed infants at high risk of developing allergy; and infants at high  
84 risk of developing allergy (8). In a systematic review from 2014 on food allergy, The European  
85 Academy of Allergy and Clinical Immunology (EAACI) did not find evidence to support the use of  
86 probiotics in the prevention of food allergy (9).

87 Overall, studies on probiotics have shown conflicting results, and the heterogeneity of studies on  
88 probiotics and the development of allergic diseases is a pitfall in the interpretation of the results  
89 (10).

90 Most studies investigating the prevention of the development of allergic diseases by probiotics  
91 administer probiotics either to the mother during pregnancy, to the infant during early infancy, or  
92 both, whereas administration in late infancy has not previously been examined.

93 As part of the ProbiComp Study (11), we aimed to investigate the effect of *Lactobacillus*  
94 *rhamnosus* (LGG) in combination with *Bifidobacterium animalis* subsp. *lactis* (BB-12)  
95 administered in late infancy – prior to attending daycare – on the development of allergic diseases  
96 and sensitization in terms of doctor’s diagnosed allergic disease, elevated specific IgE levels, and  
97 parentally observed and reported food reactions.

98

## 99 **METHODS**

100 In the following, “allergic disease” covers doctor’s diagnosed asthma, allergic rhinitis, allergic  
101 conjunctivitis, and eczema; whereas “food reaction” covers parentally observed recurrent reactions  
102 to food sources.

### 103 *Participants*

104 The ProbiComp Study is a randomized, double-blind, placebo-controlled intervention trial designed  
105 to investigate the effect of probiotics on absence from daycare due to respiratory or gastrointestinal  
106 infections in infants aged 8-14 months (11). Inclusion period was August to December 2014 and  
107 August to December 2015. Infants expected to start daycare within 12 weeks after intervention start  
108 were assigned by block randomization to receive either daily probiotics or placebo for a 6 months’  
109 period. Inclusion criteria were birthweight > 2500 g, gestational age > 36 weeks, being single-born,  
110 and expected to start in daycare at age 8-14 months between September and February. Exclusion  
111 criteria were severe chronic illness, regular medication (including proton pump inhibitors),  
112 antibiotic treatment within 4 weeks prior to baseline examination, and non-Danish speaking parents.  
113 Written, informed consent was given by parents or legal guardians of 290 participants. Baseline  
114 examination including a structured interview, anthropometric measurements, and a venous blood  
115 sample was conducted after randomization, but prior to intervention start. The procedure was  
116 repeated at the end of the intervention, 6 months later. Anthropometric measurements were weight  
117 and length, but none of these are included in the present manuscript.

118

### 119 *Intervention*

120 Intervention started the day following the baseline examination. The intervention group received  
121 sachets of 1.0 g maltodextrin supplemented with LGG and BB-12 each in a dose of  $10^9$  colony  
122 forming units (CFU), and the placebo group received maltodextrin only. LGG/BB-12 and placebo  
123 sachets were identical in appearance, smell and taste. Both LGG and BB-12 are registered  
124 trademarks of Chr. Hansen A/S (Hørsholm, Denmark) and were provided by Chr. Hansen A/S free  
125 of charge. To review the isolated effect of LGG/BB-12, fermented dairy products supplemented  
126 with probiotics were prohibited two weeks prior to and within the intervention period. Un-  
127 supplemented yogurt was allowed 1-2 times per week. There were no restrictions on the use of  
128 infant formulas, whether or not the formula contained pro- or prebiotics.

129

130 *Endpoint measures*

131 The structured interview at baseline contained questions on family and household characteristics as  
132 well as allergic disease prior to enrolment. During the intervention period of 6 months, parents were  
133 to monthly register symptoms and diagnosis of allergic disease as well as reactions to foods (milk,  
134 egg, fish, peanuts, other nuts (e.g. almonds or hazelnuts), flour products, legumes, fruit, and  
135 vegetables) in a web-based questionnaire. The questions on allergic symptoms were previously  
136 validated in a prospective birth cohort study, where infants were diagnosed with atopic eczema  
137 using five different criteria; Hanifin and Rajka, Schultz-Larsen, Danish Allergy Research Centre  
138 (DARC), doctor's diagnosed visible eczema, and (as used in the present study) the U.K. Working  
139 Party's diagnostic criteria using discriminatory features from Hanifin and Rajka in a questionnaire  
140 form (12).

141 Sensitization was defined using the ImmunoCAP® Phadiatop® Infant blood test (Phadia AB,  
142 Sweden), which is an in vitro qualitative and semi-quantitative assay for graded determination of  
143 specific IgE antibodies to food and inhalant allergens that are relevant in the development of atopy  
144 in younger children. The allergens included in the test are: cow's milk, hen's egg, peanut, shrimp,  
145 cat, dog, *Dermatophagoides pteronyssinus*, birch, timothy, ragweed, and *Parietaria judaica* (13).

146 Results are expressed as Phadia Arbitrary Units (PAU)/L indicating the degree of sensitization, and  
147 values  $\geq 0.35$  PAU/L were considered positive, i.e. the child was classified as sensitized.

148 Furthermore, specific IgE levels against a panel of food and inhalant allergens were determined  
149 (ImmunoCAP ISAC™, Thermo-Fischer Scientific, Denmark) in sensitized children.

150

151 *Statistics*

152 Descriptive statistics were performed to describe the participants, their family and household  
153 characteristics. Continuous variables are presented as mean (SD) if normally distributed, otherwise  
154 as median (IQR), categorical variables as  $n$  (%).

155 The outcomes of the present analysis within the ProbiComp Study were 1) the incidence of allergic  
156 diseases during the intervention period, 2) the incidence of sensitization, i.e. ImmunoCAP®

157 Phadiatop® test with specific IgE  $\geq$  0.35 PAU/L at the end of the intervention, 3) the incidence of  
158 food reactions during the intervention period. Finally, a composite outcome in terms of “any  
159 allergic disease”, i.e. asthma, rhinitis, conjunctivitis, and eczema was included and analyzed  
160 separately. A per protocol approach was chosen due to non-availability of outcome measurements  
161 among drop-outs. Furthermore, for every outcome, children already affected at baseline were  
162 excluded at follow-up, e.g. children with eczema at baseline were excluded when assessing the  
163 incidence of eczema during the intervention period.

164 Outcome incidences were compared by chi<sup>2</sup> test,  $p < 0.05$  was considered significant. Statistical  
165 analyses were performed using STATA IC/14.2 (Texas, USA).

166

### 167 *Ethics*

168 The study was approved by the Committees on Biomedical Research Ethics for the Capital Region  
169 of Denmark (H-4-2014-032), and registered at [www.clinicaltrials.org](http://www.clinicaltrials.org) (NCT02180581).

170

## 171 **RESULTS**

### 172 *Participants*

173 A total of 290 children were randomized, 144 to the intervention group and 146 to the placebo  
174 group. A detailed flowchart of the study recruitment is presented elsewhere (11). In summary, five  
175 children dropped out after randomization, but prior to baseline examination (1 from the probiotic  
176 and 4 from the placebo group). The remaining 285 children had a mean age of 10.1 months (SD  
177 0.7) at baseline examination and intervention start. Baseline characteristics were equally distributed  
178 in the two groups (Table 1). Of the 285 children, 25 (8.8%) dropped out during the intervention, 13  
179 from the probiotic and 12 from the placebo group. Mean age at follow-up was 16.1 months (SD  
180 0.9).

181 Fecal samples from baseline and follow-up was obtained from 201 children, and their gut  
182 microbiota composition has recently been described in detail elsewhere (14). To summarize, LGG  
183 and BB-12 was detected in 91% and 95%, respectively, of the fecal samples from the probiotic



184 group, and in 2% and 31%, respectively, of the fecal samples from the placebo group at follow-up.  
185 Noteworthy, the BB-12 primer was subspecies specific, as opposed to strain specific (14).

186

### 187 *Allergic disease*

188 Regarding allergic disease, no children were diagnosed with asthma, rhinitis, or conjunctivitis at  
189 baseline, whereas a total of 19 children were diagnosed with eczema, 11 in the probiotic and 8 in  
190 the placebo group. The follow-up groups for asthma, rhinitis, and conjunctivitis therefore comprised  
191 260 children (130 in each group), and the follow-up groups for eczema and any allergic disease  
192 comprised 241 children (119 in the probiotics and 122 in the placebo group).

193 As shown in Table 2, a total of 19 children developed eczema during the intervention; 5 (4.2%) in  
194 the probiotic group and 14 (11.5%) in the placebo group ( $p = 0.036$ ), corresponding to a relative  
195 risk of 0.37 (95% CI 0.14-0.98). The incidence of the other allergic diseases did not differ across  
196 groups. Regarding the composite endpoint “any allergic disease”, 9 (7.6%) in the probiotic group  
197 and 23 (18.9%) in the placebo group were affected ( $p = 0.010$ ), in both groups driven by eczema  
198 (55.5% and 60.9% in the probiotics and placebo group, respectively).

199

### 200 *Sensitization*

201 A total of 153 children had both baseline and follow-up IgE measured; 80 in the probiotic and 73 in  
202 the placebo group. Of these, 13 were sensitized at baseline; 6 (7.5%) in the probiotic, and 7 (9.6%)  
203 in the placebo group, and the follow-up group therefore comprised 140 children; 74 in the probiotic  
204 and 66 in the placebo group. During the intervention, two in each group developed sensitization ( $p$   
205  $= 0.910$ ).

206

### 207 *Food reactions*

208 A total of 27 children had food reactions at baseline; 13 (9.1%) in the probiotic and 14 (9.9%) in the  
209 placebo group, leaving a total of 233 children in the follow-up group; 117 in the probiotic and 116  
210 in the placebo group. Twenty-five children presented with newfood reactions during the

211 intervention according to parental report, 12 (10.2%) in the probiotic and 13 (11.2%) in the placebo  
212 group ( $p = 0.814$ ).

213

## 214 **DISCUSSION**

215 In this double-blind, placebo-controlled study, participants were randomized to receive either a  
216 mixture of two strains of probiotics (LGG/BB-12) or placebo in late infancy, prior to attending  
217 daycare. Despite the late start of administration (mean age 10.1 months), we observed a  
218 significantly lower incidence of eczema in the probiotic group compared to placebo during the  
219 intervention. Concerning other allergic diseases, we observed no differences in incidences between  
220 the groups, which could be due to a later onset of these diseases. Neither did we observe any  
221 differences in the incidences of sensitization or food reactions.

222 Whereas most other studies have included participants based on either maternal allergic disease or  
223 first degree relative with allergic disease (15-22), participants in the ProbiComp study were  
224 unselected. However, more than half of the children (in both groups) had a first degree relative with  
225 a history of allergic disease. This is in line with previous, unselected studies (23-24), and probably  
226 reflects a high frequency and awareness of allergic diseases in the population, and a greater intent to  
227 participate within families with allergic diseases.

228 The high detection rate (> 90%) of LGG/BB-12 in fecal samples of the probiotic group indicates a  
229 high level of compliance. However, BB-12 was also detected in 31% of the placebo group fecal  
230 samples at follow-up. This could be due to the BB-12 primer being subspecies and not strain  
231 specific, suggesting detection of endogenous *Bifidobacterium animalis* subsp. *lactis* or due to prior  
232 ingestion of related strains through infant formula (14). From baseline to an age of 12.8 months (SD  
233 1.4), 91 children in the placebo group used infant formulas, and of these, 26 had used formulas  
234 containing probiotics (11). Wider dietary restrictions were considered during planning of the study,  
235 i.e. prohibiting the use of infant formulas containing pre- and/or probiotics, but there was concern,  
236 that it would result in difficulties recruiting participants, since a majority of currently available  
237 infant formulas in Denmark contain pre- and/or probiotics.

238 Regarding the use of the *combination* of LGG and BB-12, Huurre *et al.* in 2008 investigated pre-  
239 and postnatal maternal administration of a combination of LGG and BB-12. Eczema was developed

240 in 17.6% of the placebo group and 9.7% of the probiotics group, though not reaching statistical  
241 significance ( $p = 0.131$ ) (25).

242 LGG used in combination with other probiotics has also yielded conflicting results. Regarding  
243 maternal administration, Dotterud *et al.* in 2010 used administration of three strains of probiotics,  
244 LGG, BB-12 and *Lactobacillus acidophilus* LA5, pre- and postnatally. The cumulative incidence of  
245 eczema at the age of two and 6 years was reduced (23, 26). Supporting this, Rautava *et al.* in 2012  
246 observed a protective effect of a combination of *Bifidobacterium longum* and LGG or a  
247 combination of *Bifidobacterium longum* and *Lactobacillus paracasei* on the development of  
248 eczema, when administered to the mother in pregnancy and during breastfeeding (20).

249 Administration of LGG and *Bifidobacterium longum* (BL999) directly to the child in infant formula  
250 from birth until 6 months of age was examined by Soh *et al.* in 2009, and no preventive effect on  
251 the development of eczema at two years of age was observed (21).

252 The use of LGG as a single strain of bacteria in relation to allergic diseases has been investigated  
253 several times. Kalliomäki *et al.* in 2001 (16) observed a protective effect of LGG on the incidence  
254 of eczema when given prenatally to the mother and after birth to the infant, whilst no effect on the  
255 development of other allergic diseases was observed. Wickens *et al.* in 2008 had similar findings  
256 for *Lactobacillus rhamnosus* strain HN001 including a protective effect up to 4 years of age (22,  
257 29). In two long term follow-up studies, Kalliomäki *et al.* observed that the preventive effect  
258 extended to 4 and 7 years of age, respectively (27-28). Yet, Kopp *et al.* in 2008 (18) and Ou *et al.* in  
259 2012 (30) did not reproduce these findings at follow-up at 2 years of age (Kopp *et al.*) and at 6, 18,  
260 and 36 months of age (Ou *et al.*).

261 To our knowledge, only one other study has investigated the effects of probiotics administered in  
262 late infancy on the development of allergic disease. West *et al.* used *Lactobacillus paracasei* ssp.  
263 administered during weaning, i.e. from four to 13 months of age, and observed a reduced incidence  
264 of eczema at 13 months of age (24).

265 Regarding sensitization, our null-findings are in line with findings from previous studies (15-16, 18-  
266 21, 24, 30). This is also the case with food reactions, where we observed no differences between the  
267 two groups. Kukkonen *et al.* observed no differences on the development of food allergies between  
268 probiotics and placebo groups, providing the probiotics for the mother 2-4 weeks prior to delivery  
269 and to the infant for 6 months thereafter (19). Cuello-Garcia *et al.* did not find evidence in a

270 systematic review and meta-analysis to support the effects of probiotics to reduce the risk of allergic  
271 diseases, other than eczema (7). Finally, EAACI does not support the use of probiotics in the  
272 prevention of food allergy in their guidelines (9).

273 A limitation of the present analysis is that sample size was based on the primary outcome of the  
274 ProbiComp study, i.e. absence from daycare due to infections (11). Despite this, we observed  
275 significant differences in the development of eczema, and regarding allergic diseases other than  
276 eczema, we probably would not have benefited from a larger sample size, since asthma, rhinitis, and  
277 conjunctivitis usually do not develop until later in childhood, and food reactions are likely to have  
278 already occurred prior to the intervention period. Furthermore, as often observed in randomized  
279 controlled trials including healthy individuals, the ProbiComp study population was self-selected  
280 and consisted of primarily well-educated, high-income families with a special interest in the study  
281 and study participation in general. This may explain the high number of participants completing the  
282 study, which is indeed a strength.

283 In conclusion, we observed that administration for 6 months of a combination of two strains of  
284 probiotics (LGG and BB-12) starting in late infancy prior to attending daycare, had a preventive  
285 effect on the development of doctor's diagnosed eczema, but no effects on other allergic diseases,  
286 sensitization or recurrent food reactions. The late timing of the administration of probiotics suggests  
287 an even broader window of opportunity in the prevention of eczema by use of probiotics.

288

## 289 **AUTHORS' CONTRIBUTIONS**

290 Ms Meineche Schmidt conducted the analyses and drafted the initial manuscript. Dr Laursen  
291 coordinated and conducted the data collection. Ms Bruun provided statistical guidance, critically  
292 reviewed and revised the manuscript. Drs Larnkjær, Mølgaard, Michaelsen, and Høst  
293 conceptualized and designed the study and critically reviewed the manuscript. All authors approved  
294 the final manuscript and revision.

295

## 296 **CONFLICTS OF INTEREST**

297 The study was funded by Innovation Fund Denmark, University of Copenhagen, and Chr. Hansen  
298 A/S. Drs Mølgaard and Michaelsen received a grant from Chr. Hansen A/S for the current study and  
299 for another study with probiotics in Ugandan children with severe acute malnutrition. Chr. Hansen  
300 A/S had no involvement in analyses of data. The other authors report no conflicts of interest  
301 relevant to this article.

## 302 REFERENCES

- 303 1. [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/NHIS/SHS/2014\\_SHS\\_Table\\_C-](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2014_SHS_Table_C-2.pdf)  
304 2.pdf (accessed September 11th 2017)
- 305 2. Henriksen L, Simonsen J, Haerskjold A, *et al.* Incidence rates of atopic dermatitis,  
306 asthma, and allergic rhinoconjunctivitis in Danish and Swedish children. *J Allergy Clin Immunol*  
307 2015;136(2):360-366.
- 308 3. Sicherer SH, Noone SA, Muñoz-Furlong A. The impact of childhood food allergy on  
309 quality of life. *Ann Allergy Asthma Immunol* 2001 Dec;87(6):461-464.
- 310 4. Silva CH, Silva TE, Morales NM, Fernandes KP, Pinto RM. Quality of life in children  
311 and adolescents with allergic rhinitis. *Braz J Otorhinolaryngol* 2009 Sep-Oct;75(5):642-649.
- 312 5. [http://www.who.int/foodsafety/fs\\_management/en/probiotic\\_guidelines.pdf](http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf) (accessed  
313 August 11th 2017)
- 314 6. Pelucchi C, Chatenoud L, Turati F, *et al.* Probiotics supplementation during  
315 pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. *Epidemiology* 2012  
316 May;23(3):402-414.
- 317 7. Cuello-Garcia CA, Brožek JL, Fiocchi A, *et al.* Probiotics for the prevention of  
318 allergy: A systematic review and meta-analysis of randomized controlled trials. *J Allergy Clin*  
319 *Immunol* 2015 Oct;136(4):952-961.
- 320 8. Fiocchi A, Pawankar R, Cuello-Garcia C, *et al.* World Allergy Organization-  
321 McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics. *World*  
322 *Allergy Organ J* 2015 Jan 27;8(1):4.

- 323 9. Muraro A, Halken S, Arshad SH, *et al.* EAACI food allergy and anaphylaxis  
324 guidelines. Primary prevention of food allergy. *Allergy* 2014 May;69(5):590-601.
- 325 10. Forsberg A, West CE, Prescott SL, Jenmalm MC. Pre- and probiotics for allergy  
326 prevention: time to revisit recommendations? *Clin Exp Allergy* 2016 Dec;46(12):1506-1521.
- 327 11. Laursen RP, Larnkjaer A, Ritz C, Hauger H, Michaelsen KF, Mølgaard C. Probiotics  
328 and child care absence due to infections: A randomized controlled trial. *Pediatrics* 2017  
329 Aug;140(2).
- 330 12. Jöhnke H, Vach W, Norberg LA, Bindslev-Jensen C, Høst A, Andersen KE. A  
331 comparison between criteria for diagnosing atopic eczema in infants. *Br J Dermatol* 2005  
332 Aug;153(2):352-358.
- 333 13. Halvorsen R, Jenner A, Hagelin EM, Borres MP. Phadiatop infant in the diagnosis of  
334 atopy in children with allergy-like symptoms. *Int J Pediatr* 2009;2009:460737.
- 335 14. Laursen MF, Laursen RP, Larnkjaer A, Michaelsen KF, Bahl MI, Licht TR.  
336 Administration of two probiotic strains during early childhood does not affect the endogenous gut  
337 microbiota composition despite probiotic proliferation. *BMC Microbiol* 2017 Aug 17;17(1):175.
- 338 15. Abrahamsson TR, Jakobsson T, Böttcher MF, *et al.* Probiotics in prevention of IgE-  
339 associated eczema: a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*  
340 2007 May;119(5):1174-1180.
- 341 16. Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics  
342 in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet* 2001 Apr  
343 7;357(9262):1076-1079.
- 344 17. Kim JY, Kwon JH, Ahn SH, *et al.* Effect of probiotic mix (*Bifidobacterium bifidum*,  
345 *Bifidobacterium lactis*, *Lactobacillus acidophilus*) in the primary prevention of eczema: a double-  
346 blind, randomized, placebo-controlled trial. *Pediatr Allergy Immunolog* 2010 Mar;21(2 Pt 2):e386-  
347 393.
- 348 18. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind,  
349 placebo-controlled trial of probiotics for primary prevention: no clinical effects of *Lactobacillus GG*  
350 supplementation. *Pediatrics* 2008 Apr;121(4):e850-856.

- 351 19. Kukkonen K, Savilahti E, Haahtela T, *et al.* Probiotics and prebiotic galacto-  
352 oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-  
353 controlled trial. *J Allergy Clin Immunol* 2007 Jan;119(1):192-198.
- 354 20. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation  
355 during pregnancy and breast-feeding reduces the risk of eczema in the infant. *J Allergy Clin*  
356 *Immunol* 2012 Dec;130(6):1355-1360.
- 357 21. Soh SE, Aw M, Gerez I, *et al.* Probiotic supplementation in the first 6 months of life  
358 in at risk Asian infants--effects on eczema and atopic sensitization at the age of 1 year. *Clin Exp*  
359 *Allergy* 2009 Apr;39(4):571-578.
- 360 22. Wickens K, Black PN, Stanley TV, *et al.* A differential effect of 2 probiotics in the  
361 prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. *J Allergy*  
362 *Clin Immunol* 2008 Oct;122(4):788-794.
- 363 23. Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent  
364 allergic disease: a randomized, double-blind trial. *Br J Dermatol* 2010 Sep;163(3):616-623.
- 365 24. West CE, Hammarström ML, Hernell O. Probiotics during weaning reduce the  
366 incidence of eczema. *Pediatr Allergy Immunol* 2009 Aug;20(5):430-437.
- 367 25. Huurre A, Laitinen K, Rautava S, Korkeamäki M, Isolauri E. Impact of maternal  
368 atopy and probiotic supplementation during pregnancy on infant sensitization: a double-blind  
369 placebo-controlled study. *Clin Exp Allergy* 2008 Aug;38(8):1342-1348.
- 370 26. Simpson MR, Dotterud CK, Storrø O, Johnsen R, Øien T. Perinatal probiotic  
371 supplementation in the prevention of allergy related disease: 6 year follow up of a randomised  
372 controlled trial. *BMC Dermatol* 2015 Aug 1;15:13.
- 373 27. Kalliomäki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and  
374 prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet*  
375 2003 May 31;361(9372):1869-1871.
- 376 28. Kalliomäki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of  
377 life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. *J Allergy Clin*  
378 *Immunol* 2007 Apr;119(4):1019-1021.

- 379 29. Wickens K, Black P, Stanley TV, *et al.* A protective effect of *Lactobacillus*  
380 *rhamnosus* HN001 against eczema in the first 2 years of life persists to age 4 years. *Clin Exp*  
381 *Allergy* 2012 Jul;42(7):1071-1079.
- 382 30. Ou CY, Kuo HC, Wang L, *et al.* Prenatal and postnatal probiotics reduces maternal  
383 but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. *Clin Exp*  
384 *Allergy* 2012 Sep;42(9):1386-1396.

Author Manuscript



**Table 1 – Baseline characteristics**

All values are n (%) unless otherwise stated. Percentages are based on the group total.

	<b>Probiotics</b>	<b>Placebo</b>
N	143	142
<b>Household characteristics</b>		
First degree relative with allergic disease <sup>1</sup>	83 (58.0)	81 (57.0)
Older sibling(s)	71 (49.7)	66 (46.5)
Parental smoking, indoor	1 (0.7)	0 (0.0)
Parental smoking, outdoor	13 (9.1)	14 (9.9)
Furry pet <sup>2</sup>	26 (18.2)	25 (17.6)
Age at baseline, months mean (SD)	9.98 (0.81)	10.08 (0.88)
<b>Birth characteristics</b>		
Vaginal birth	111 (77.6)	121 (85.2)
Female sex	69 (48.3)	71 (50.0)
Birth weight, grams mean (SD)	3,543 (492)	3,532 (456)
<b>Nutrition characteristics</b>		
Currently breastfed	72 (50.3)	63 (44.3)
Duration of exclusive breastfeeding, months median (IQR)	4.0 (1.0-5.0)	4.0 (1.0-4.9) <sup>3</sup>

Use of infant formula at baseline	92 (64.3)	102 (71.8)
with probiotics	36 (25.2)	36 (25.4)
with prebiotics	50 (35.0)	60 (42.3)
No use of infant formula at baseline	6 (4.2)	6 (4.2)

1) Asthma, rhinitis, conjunctivitis, or eczema

2) E.g. cat, dog, guinea pig, rabbit

3) n = 140

**Table 2 – Doctor’s diagnosed allergic disease at follow-up**

All values are n (%) unless otherwise stated. Percentages are based on the group total. A per protocol approach was chosen, i.e. N are study population at baseline and follow-up n are study population for the specific endpoint after exclusion of censored cases (those who withdrew prior to follow-up and those who were already diagnosed at baseline). P values are for chi<sup>2</sup> test.

	<b>Probiotics</b>	<b>Placebo</b>	<b>p</b>
N	143	142	-
Drop-out prior to follow-up	13	12	
<b>Asthma</b>			
Follow-up n	130	130	0.309
Diagnosed at follow-up	3 (2.3)	6 (4.6)	
<b>Rhinitis</b>			
Follow-up n	130	130	-
Diagnosed at follow-up	0 (0)	0 (0)	
<b>Conjunctivitis</b>			
Follow-up n	130	130	0.314
Diagnosed at follow-up	1 (0.8)	3 (2.3)	
<b>Eczema</b>			
Follow-up n	119	122	0.036
Diagnosed at follow-up	5 (4.2)	14 (11.5)	
<b>Any allergic disease</b>			
Follow-up n	119	122	0.010
Diagnosed at follow-up	9 (7.6)	23 (18.9)	